Search

For Corporates
Analyzing Healthcare M&A Trends: Q1 2024 Insights
Healthcare M&A activity remained robust in the first quarter of 2024, with 29 transactions vs. 28 in 2023. Biopharma was the most active healthcare subsector, representing 45% of deal volume, while Services activity remained dampened despite notable transactions such as Novo Holdings’ acquisition of Catalent. We expect Biopharma M&A activity to remain robust as large pharmaceutical companies attempt to fill revenue and pipeline gaps via acquisitions of late- or commercial-stage companies. We expect pre-commercial biopharma companies to continue pursue strategic alternatives, including mergers, private company mergers and cash-out transactions as a result of the dynamic capital markets environment.
LEARN MORE
For Investors
Sectors
Insights
About
- Firm
- Careers
- News
- Contact
- Transactions

Transactions

Deal Showcase

Biopharma DNA strand composition

More Transactions

$125 Million

Joint Bookrunner

Follow-On

February 2023

$119 Million

Joint Bookrunner

Follow-On

October 2021

$150 Million

Joint Bookrunner

Follow-On

December 2023

$35 Million

Exclusive Financial Advisor

Series C Financing Led by MultiPlan Corporation

June 2022

View all Transactions

Featured Insights

Leerink Partners Insights Into Healthcare Trends Hero Image Abstract Stock Chart

Insights into Healthcare M&A: Q2 2024 Trends

Leerink Partners Research analyst looking at data on a computer screen

Featured Research

Biopharma / Immunology & Metabolism / Live from EULAR: Quick Takeaways from KYV-101 Data Update

Leerink Podcast Maya Hardigan Featured Image

Mae Founder & CEO Maya Hardigan

VIEW ADDITIONAL INSIGHTS